These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma. Tomisaki I; Harada M; Minato A; Nagata Y; Kimuro R; Higashijima K; Harada K; Fujimoto N Anticancer Res; 2022 Mar; 42(3):1629-1634. PubMed ID: 35220261 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy. Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011 [TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Balar AV; Kamat AM; Kulkarni GS; Uchio EM; Boormans JL; Roumiguié M; Krieger LEM; Singer EA; Bajorin DF; Grivas P; Seo HK; Nishiyama H; Konety BR; Li H; Nam K; Kapadia E; Frenkl T; de Wit R Lancet Oncol; 2021 Jul; 22(7):919-930. PubMed ID: 34051177 [TBL] [Abstract][Full Text] [Related]
17. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001 [TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625 [TBL] [Abstract][Full Text] [Related]
19. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359 [TBL] [Abstract][Full Text] [Related]
20. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]